{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-281960","form_type":"8-K","ticker":"WVE","cik":"0001631574","company_name":"Wave Life Sciences Ltd.","filed_at":"2022-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.503122+00:00","generated_at":"2026-06-21T23:04:27.717255+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Wave Life Sciences Q3 2022 net loss $39M; HD trial shows allele-selective mHTT reduction","bullets":["Net loss of $39.0M vs $6.2M in Q3 2021; revenue $0.3M down from $36.4M due to Takeda amendment.","SELECT-HD: WVE-003 reduced mHTT by mean 22% (median 30%) at 85 days post single dose; wtHTT preserved.","WVE-N531 multidosing underway in DMD; muscle biopsy data expected in 4Q 2022.","Selected WVE-006 as first RNA editing candidate for AATD; CTA submissions expected in 2023.","Cash $122.0M as of Sept 30, 2022; runway expected to fund operations to end of 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-281960","json":"https://secwatch.observer/filing/0001193125-22-281960.json","markdown":"https://secwatch.observer/filing/0001193125-22-281960.md","text":"https://secwatch.observer/filing/0001193125-22-281960.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1631574/000119312522281960/0001193125-22-281960-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1631574/000119312522281960/d366748d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T23:04:27.717255+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0007440c290391461c32adc070d24efe784704d3","claim":"Wave Life Sciences Ltd. reported financial results for the quarter ended September 30, 2022.","evidence_excerpt":"On November 10, 2022, Wave Life Sciences Ltd. (the “Company”) announced its financial results for the quarter ended September 30, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1631574/000119312522281960/0001193125-22-281960-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}